Company Analysis
Sign in

ImmunityBio, Inc. (IBRX)

Nasdaq: IBRX · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2005
Full chart Alerts Compare
Grade5.5
◀ Past 5.2● Present 5.1▶ Future 6.2
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

283 patents granted to the 20 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to ImmunityBio, Inc.’s names, not what it holds today.

Patents granted
283
279 utility, 4 design, 1976 to Dec 31, 2025
Granted in 2025
48
Against 40 in 2024 and 24 in 2023
Applications published
431
49 of them in 2025
Names they are printed under
20
its own name, a subsidiary, a former name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals85
Biotechnology47
Computer technology14
Medical technology14
Analysis of biological materials8
Control1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name20 counted
ImmunityBio, Inc. its own name
US, as the owner printed on each patent
58 granted
43 published
GlobeImmune, Inc. a subsidiary
US, as the owner printed on each patent
60 granted
35 published
Altor Bioscience LLC a subsidiary
US, as the owner printed on each patent
61 granted
16 published
NantCell, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
70 published
Altor Bioscience Corporation a subsidiary
named as the applicant on its applications, in US
0 granted
62 published
NantCell, Inc. a subsidiary
US, as the owner printed on each patent
42 granted
11 published
ImmunityBio, Inc. its own name
named as the applicant on its applications, in US
0 granted
48 published
NantKwest, Inc. a former name
named as the applicant on its applications, in US
0 granted
41 published
Nantkwest, Inc. a former name
US, as the owner printed on each patent
17 granted
18 published
GLOBEIMMUNE, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
32 published
Etubics Corporation a subsidiary
US, as the owner printed on each patent
19 granted
5 published
ETUBICS CORPORATION a subsidiary
named as the applicant on its applications, in US
0 granted
21 published
Access Bio, Inc. a subsidiary
US, as the owner printed on each patent
13 granted
6 published
VBC HOLDINGS LLC a subsidiary
US, as the owner printed on each patent
5 granted
5 published
VIVABIOCELL S.P.A. a subsidiary
IT, as the owner printed on each patent
7 granted
3 published
Access Bio, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
5 published
VIVABIOCELL S.p.A. a subsidiary
named as the applicant on its applications, in IT
0 granted
5 published
VBC HOLDINGS LLC a subsidiary
named as the applicant on its applications, in US
0 granted
3 published
Conkwest, Inc. a former name
US, as the owner printed on each patent
1 granted
1 published
IGDRASOL, INC. a subsidiary
US, as the owner printed on each patent
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,509,494Multi-chain chimeric polypeptides and uses thereofBiotechnologyImmunityBio, Inc.
Dec 23, 202512,503,680Methods and systems for cell bed formation during bioprocessingBiotechnologyImmunityBio, Inc.
Dec 16, 202512,498,363Combined invasion and cytotoxicity assay using chemokine secreting target cellsMedical technologyImmunityBio, Inc.
Dec 16, 202512,497,462Anti-CD26 proteins and uses thereofMedical technologyImmunityBio, Inc.
Dec 9, 202512,492,377Modified NK-92 haNK003 cells for the clinicBiotechnologyImmunityBio, Inc.
Dec 9, 202512,491,201Maximizing T-cell memory and compositions and methods thereforPharmaceuticalsNantCell, Inc.
Dec 2, 202512,487,241Rapid verification of virus particle production for a personalized vaccineAnalysis of biological materialsNantCell, Inc.
Nov 25, 202512,479,899Multi-chain chimeric polypeptides and uses thereofBiotechnologyImmunityBio, Inc.
Nov 18, 202512,473,348Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cellsBiotechnologyImmunityBio, Inc.
Nov 18, 202512,473,347Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cellsBiotechnologyImmunityBio, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 18, 20252025/0383359COVID-19 Mucosal Antibody AssayAnalysis of biological materialsNantCell, Inc.
Nov 20, 20252025/0352618METHODS OF TREATING BRONCHOPULMONARY DYSPLASIAPharmaceuticalsImmunityBio, Inc.
Nov 6, 20252025/0342930DISTRIBUTED LEDGER FOR MEDICAMENT ADMINISTRATION TRACKINGControlImmunityBio, Inc.
Nov 6, 20252025/0340664GENETICALLY MODIFIED NK-92 CELL LINEPharmaceuticalsImmunityBio, Inc.
Nov 6, 20252025/0339369Neoepitope Vaccine Delivery Vehicle and Methods of Making the SamePharmaceuticalsImmunityBio, Inc.
Oct 9, 20252025/0313603Primary NK CAR Constructs And MethodsBiotechnologyImmunityBio, Inc.
Oct 9, 20252025/0312418INTERLEUKIN-15 SUPERAGONIST N-803 IN PEOPLE EXPERIENCING LONG COVIDPharmaceuticalsImmunityBio, Inc.
Sep 25, 20252025/0298030Compositions and Methods for NK-92 Cells Expressing Native CD16BiotechnologyImmunityBio, Inc.
Sep 4, 20252025/0278468CONTENT AUTHENTICATION AND VALIDATION VIA MULTI-FACTOR DIGITAL TOKENS, SYSTEMS, AND METHODSComputer technologyImmunityBio, Inc.
Aug 28, 20252025/0270282ELIMINATION OF CD19-POSITIVE LYMPHOID MALIGNANCIES BY CD19-CAR EXPRESSING NK CELLSBiotechnologyImmunityBio, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 39 · Biotechnology 26 · Medical technology 16 · Computer technology 12 · Analysis of biological materials 7 · Control 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton IBRX · research, not advice